TELA - Additional data shows durable outcome for TELA Bio' tissue matrix for hernia repair

TELA Bio (TELA) has announced additional data from its BRAVO study with OviTex tissue matrix. Data were presented at the Americas Hernia Society Annual Meeting.30-day data from 85 subjects demonstrated that ventral hernia repair using OviTex resulted in low incidence of surgical site infections and occurrences. None (0%) patient experienced a hernia recurrence within the first 30-days. Among patients who experienced an infection/occurrence at 30 days, none required surgical intervention or implant removal.The company also announced long-term outcomes data for the initial 20 hernia repair patients using OviTex. Among these patients, no patient experienced a hernia recurrence. Five patients experienced an occurrence during the two years, though none required surgical intervention or implant removal.

For further details see:

Additional data shows durable outcome for TELA Bio' tissue matrix for hernia repair